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Introduction
Low levels of vitamin D in breast milk (20- IU/day effectively enriches the breast milk with appropriate levels of vitamin D to satisfy the breastfed infant's requirements, 3, 4, 6 and this approach is often preferred by mothers over infant supplementation. 7 Cholecalciferol (not 25(OH)D or 1,25(OH) 2 D), which crosses readily from maternal circulation into breast milk, is the form available to the infant.
Vitamin D differs in its side chain substitution based on the vitamin's source wherein the plant derived form is called vitamin D 2 and mammalian form is called vitamin D 3 . Metabolism of both forms are follow the same biochemical route in humans. 8 Vitamin D and parathyroid hormone (PTH) are essential for normal calcium and phosphorus homeostasis. 9 Vitamin D 3 is synthesized in the skin by ultraviolet-light mediated photo-isomerization of 7-hydrocholesterol 9, 10 and is metabolized in the liver to 25 
Methods and Materials
Subjects and samples: The study was a randomized controlled trial in 40 lactating females, ages 24-40 years, with a singleton infant between the ages of 1 and 6 months. Subjects were randomized to receive vitamin D 3 as a single oral dose of 150,000 IU (N = 20), or 5000 IU daily (N = 20) for 28 days. Additional details regarding the study design have been previously described. 4 The Mayo Clinic Institutional Review Board approved the study. A C C E P T E D M A N U S C R I P T were measured by the methods described above. 17 All patients included in the reference range study were screened by a detailed chart review to ascertain that none of the individuals from whom samples were obtained were taking drugs known to affect mineral metabolism or had systemic conditions known to affect mineral metabolism. They were not taking vitamin D or calcium supplements, or if they were, were taking no more than 1000 mg calcium per day and 1000 IU vitamin D 3 per day.
Statistical analysis: Data were entered in and analyzed with Excel 2010 (Microsoft Corp., Redmond, WA). The Student t test was used to compare continuous variables between the two treatment groups. P values less than 0.05 were considered significant.
Results
Baseline characteristics of the study participants are shown in whereas an opposite (direct) correlation (r 2 =0.13, p<0.001; Figure 2d ) was observed in the daily
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Discussion
We found evidence of greater production of 24,25(OH) 2 was directly correlated to 25(OH)D 3 . Evidence of a lag in 24-hydroxylation was similarly found during the early phase of supplementation. This was attributed to the slower reaction kinetics of CYP24A1 (24-hydroxylase) compared to CYP27A1 (25-hydroxylase). 28 The effect of a greater
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